Correlation analysis between 2D and quasi-3D gamma evaluations for both intensity-modulated radiation therapy and volumetric modulated arc therapy

Jung-in Kim1,2,3, Chang Heon Choi1,2,3,4, Hong-Gyun Wu1,2,3,5, Jin Ho Kim1,2,3, Kyubo Kim6 and Jong Min Park1,2,3,4

1 Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea
2 Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea
3 Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
4 Center for Convergence Research on Robotics, Advanced Institutes of Convergence Technology, Suwon, Republic of Korea
5 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
6 Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul, Republic of Korea

Correspondence to: Jong Min Park, email: leodavinci@naver.com

Keywords: 2D gamma evaluation, quasi-3D gamma evaluation, pre-treatment patient-specific quality assurance, intensity-modulated radiation therapy, volumetric modulated arc therapy

Received: July 04, 2016  Accepted: September 21, 2016  Published: September 27, 2016

ABSTRACT

The aim of this work was to investigate correlations between 2D and quasi-3D gamma passing rates. A total of 20 patients (10 prostate cases and 10 head and neck cases, H&N) were retrospectively selected. For each patient, both intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) plans were generated. For each plan, 2D gamma evaluation with radiochromic films and quasi-3D gamma evaluation with fluence measurements were performed with both 2%/2 mm and 3%/3 mm criteria. Gamma passing rates were grouped together according to delivery techniques and treatment sites. Statistical analyses were performed to examine the correlation between 2D and quasi-3D gamma evaluations. Statistically significant difference was observed between delivery techniques only in the quasi-3D gamma passing rates with 2%/2 mm. Statistically significant differences were observed between treatment sites in the 2D gamma passing rates (differences of less than 8%). No statistically significant correlations were observed between 2D and quasi-3D gamma passing rates except the VMAT group and the group including both IMRT and VMAT (r = 0.564 with \( p = 0.012 \) for the VMAT group and \( r = 0.372 \) with \( p = 0.020 \) for the group including both IMRT and VMAT), however, those were not strong. No strong correlations were observed between 2D and quasi-3D gamma evaluations.

INTRODUCTION

Both intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) techniques provide excellent dose conformity to the target volume while minimizing the dose to normal tissue [1]. The IMRT technique achieves optimal dose distributions by modulating multi-leaf collimator (MLC) positions while VMAT generates optimal dose distributions by modulating MLC positions, gantry rotation speeds and dose rates, simultaneously [2]. These modulated delivery techniques can involve large uncertainties in the treatment planning process as well as beam delivery [3-5]. Therefore, patient-specific quality assurance (QA) before treatment has been strongly recommended for both IMRT and VMAT to verify plan delivery accuracy [6-10].

As a verification method for IMRT plans, 2D gamma evaluation by measuring a planar dose distribution has been widely adopted in the clinic [11]. However, recent studies by Stasi et al. and Nelms et al. demonstrated that no correlation was observed between the results of 2D gamma evaluation and clinically relevant patient dose...
errors for IMRT [12, 13]. For VMAT, Mancuso et al. demonstrated that there were no statistically significant differences in the 2D gamma passing rates between IMRT and VMAT [8]. Betzel et al. showed that VMAT deliveries were more tolerant to variations in gantry positions and MLC leaf positions than IMRT deliveries [14]. Heilemann et al. and Fredh et al. recommended stricter 2D gamma criterion should be used for pre-treatment QA of VMAT plans than IMRT QA [15, 16]. They recommended to use a gamma criterion of 2%/2 mm for VMAT plans rather than 3%/3 mm which is widely used for 2D gamma evaluation of IMRT plans in the clinic. Kim et al. recommended to use a 2D gamma criterion of 2%/1 mm for stereotactic ablative radiotherapy (SABR) with VMAT techniques using fine resolution MLCs such as high-definition MLC™ (HD-MLC™, Varian Medical Systems, Palo Alto, CA, USA) [17]. The consensus on pre-treatment QA for VMAT and IMRT still seems to be ambiguous and disputable.

Besides 2D gamma evaluation, various verification methodologies for IMRT and VMAT have been suggested. Several groups suggested to analyze log files registered by the linac control system during beam delivery for the verification of IMRT or VMAT deliveries [18, 19]. However, this methodology has inherent limitations because the verification system and the beam delivery system are not independent of each other. The other approach is to calculate modulation indices [4, 5, 20-24]. The modulation index has limitations since it is based on the calculation with parameters acquired from treatment plans not the measurement. In other words, delivery accuracy can be predicted with the modulation index, however, we cannot verify actual delivery accuracy during beam delivery with the modulation index. For example, the modulation index cannot detect errors such as a network error or machine malfunction. On the other hand, 3D or quasi-3D gamma evaluations can be performed with recently introduced commercial dosimeters or 3D gel dosimeters. Gel dosimeters can acquire 3D dose distributions directly, however, measuring accuracy is not high enough to be used in the clinic yet [25, 26]. Nakaguchi et al. validated the COMPASS™ system (IBA Dosimetry, GmbH, Germany) for pre-treatment patient-specific IMRT QA, which is a quasi-3D dose verification system. Sdrolia et al. reported institutional tolerances for prostate VMAT QA using the COMPASS™ system [27]. Gueorguiev et al. compared the sensitivity of the results acquired using the COMPASS™ system to the point dose measurements and 2D gamma evaluations for IMRT [28].

The previous studies validated the quasi-3D verification method for IMRT and VMAT, however, no study has been performed to investigate the correlation between the results of 2D and quasi-3D gamma methods based on patient CT images for both IMRT and VMAT [29-31]. Rajasekaran et al. performed correlation analysis between 2D and 3D gamma evaluation metrics for VMAT. However, the analysis was not performed based on the patient CT images since they used the OCTAVIUS 4D™ system (PTW, Freiburg, Germany) [32]. Similarly, Jin et al. also performed correlation analysis between 2D and quasi-3D gamma evaluations, however, it was performed only for VMAT plans with the ArcCHECK™ and 3DVH™ software (Sun Nuclear Corporation, Melbourne, FL, USA) [33]. Therefore, we performed a comprehensive correlation analysis between 2D and quasi-3D gamma evaluations for pretreatment patient-specific QA for both IMRT and VMAT plans using the COMPASS™ system in this study. In addition, we investigated the tendency of 2D and quasi-3D gamma evaluations according to the modulation degree of treatment plans as well as the delivery technique.

## RESULTS

### Log file analysis

The deviation of the MLC leaf position was less than 2.5 mm for all delivered fields including both IMRT and VMAT. The mean and maximum root mean square (RMS) values of MLC leaf motion errors were 0.5 mm and 0.8 mm, respectively, for both IMRT and VMAT. In the case of VMAT, the largest MU deviation was observed at the starting control point of each arc for VMAT delivery, which ranged from -0.06 MU to 0.08 MU. The largest gantry angle deviation was also observed at the starting control point, ranging from -0.8° to 0.9°. Between the original dose distributions of a treatment plan and the reconstructed dose distributions with log files, no clinically significant differences were observed.

### 2D gamma evaluation

Data for 2D gamma evaluations with EBT2 films are shown in Table 1. An example of 2D gamma evaluation of prostate VMAT with 3%/3 mm is shown in Figure 1. The prostate group with both 2%/2 mm and 3%/3 mm and the VMAT group with 2%/2 mm followed the normal distribution of the Shapiro-Wilk test (p > 0.05).

For the delivery technique, no differences in gamma passing rates with both 2%/2 mm and 3%/3 mm were observed between IMRT and VMAT (all with p > 0.05). For the treatment site, the averaged gamma passing rate of the prostate group with both 2%/2 mm and 3%/3 mm were considerably better than those of the H&N group with statistical significance (89.1% ± 5.5% vs. 81.9% ± 10.0% with p = 0.03 for 2%/2 mm and 96.5% ± 2.1% vs. 90.9% ± 7.2% with p = 0.008 for 3%/3 mm). This was due to the high modulation of H&N plans than that of prostate plans, which was the same result as the previous study [20].

The corresponding confidence limits (CLs) for each analysis were calculated with proper confidence coefficient
respectively. As shown in the Table 1, institutional tolerance levels for IMRT and prostate plans were higher than those for VMAT and H&N plans, respectively, since the average gamma passing rate of IMRT and prostate plans were higher than those of VMAT and H&N plans.

Table 1: Summary of 2D gamma evaluation with EBT2 films as well as quasi-3D gamma evaluation with the COMPASS™ system

| Group     | N  | Passing rate (%) | p value of Shapiro-Wilk test | p value of statistical significance of difference (Wilcoxon test) | Confidence limit (%) |
|-----------|----|------------------|------------------------------|-----------------------------------------------------------------|----------------------|
| 2D Gamma evaluation with 2%/2 mm |
| IMRT      | 20 | 86.4 ± 8.3       | 0.013                        | 0.658                                                           | 69.1                 |
| VMAT      | 20 | 84.6 ± 9.2       | 0.084                        |                                                                  | 66.5                 |
| Prostate  | 20 | 89.1 ± 5.5       | 0.775                        | 0.030                                                           | 78.2                 |
| H&N       | 20 | 81.9 ± 10.0      | 0.039                        |                                                                  | 61.0                 |
| Total     | 40 | 85.6 ± 8.7       | 0.002                        |                                                                  | 68.0                 |
| 2D Gamma evaluation with 3%/3 mm |
| IMRT      | 20 | 94.5 ± 5.2       | < 0.001                      | 0.469                                                           | 83.7                 |
| VMAT      | 20 | 93.0 ± 6.5       | 0.002                        |                                                                  | 79.4                 |
| Prostate  | 20 | 96.5 ± 2.1       | 0.200                        | 0.008                                                           | 92.3                 |
| H&N       | 20 | 90.9 ± 7.2       | 0.002                        |                                                                  | 75.9                 |
| Total     | 40 | 93.8 ± 5.9       | < 0.001                      |                                                                  | 81.9                 |
| 3D Gamma evaluation with 2%/2 mm |
| IMRT      | 20 | 98.6 ± 0.7       | 0.011                        | 0.006                                                           | 97.1                 |
| VMAT      | 20 | 96.6 ± 4.1       | < 0.001                      |                                                                  | 88.0                 |
| Prostate  | 20 | 98.5 ± 0.4       | 0.276                        | 0.295                                                           | 97.7                 |
| H&N       | 20 | 96.7 ± 4.2       | < 0.001                      |                                                                  | 87.9                 |
| Total     | 40 | 97.6 ± 3.0       | < 0.001                      |                                                                  | 91.5                 |
| 3D Gamma evaluation with 3%/3 mm |
| IMRT      | 20 | 99.6 ± 0.3       | 0.091                        | 0.191                                                           | 99.0                 |
| VMAT      | 20 | 99.0 ± 1.1       | 0.005                        |                                                                  | 96.7                 |
| Prostate  | 20 | 99.6 ± 0.3       | 0.128                        |                                                                  | 99.0                 |
| H&N       | 20 | 99.0 ± 1.1       | 0.003                        | 0.127                                                           | 96.7                 |
| Total     | 40 | 99.3 ± 0.9       | < 0.001                      |                                                                  | 97.5                 |

Abbreviations: N, the number of analysis plans; IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arc therapy; H&N, head and neck

Quasi-3D gamma evaluation

Data for quasi-3D gamma evaluations with the COMPASS™ system are shown in Table 1. An example of quasi-3D gamma evaluation with 3%/3 mm as well as dose volume histograms (DVHs) of prostate VMAT is shown in Figure 2. All the quasi-3D gamma passing rates

www.impactjournals.com/oncotarget
Figure 1: A prostate volumetric modulated arc therapy (VMAT) example of 2D gamma evaluation with a gamma criterion of 3%/3 mm using EBT2 films is shown. a. the calculated dose distribution with a treatment planning system. b. measured dose distribution with EBT2 films. c. gamma map. In the gamma map, the passed and failed points are shown in green and red, respectively.

Figure 2: A prostate volumetric modulated arc therapy (VMAT) example of quasi-3D gamma evaluation with a gamma criterion of 3%/3 mm using the COMPASS system is shown. a. the calculated dose distribution with a treatment planning system. b. reconstructed dose distribution with measured fluences. c. gamma map. d. dose volume histograms (DVHs). The DVHs of the target volume, rectal wall, bladder and femoral heads are shown in red, green, yellow and brown, respectively. The dashed and solid lines represent the DVHs calculated from the original treatment plan and the reconstructed, respectively.
were higher than those of the 2D gamma passing rates. The prostate group with both 2%/2 mm and 3%/3 mm and the IMRT group with 3%/3 mm followed the normal distribution of the Shapiro-Wilk test ($p > 0.05$).

For the delivery technique, the average gamma passing rate of the IMRT group with 2%/2 mm was slightly higher than that of the VMAT group with statistical significance (98.6% ± 0.7% vs. 96.6% ± 4.1% with $p = 0.006$). For the treatment site, no statistically significant difference was not observed (all with $p > 0.05$).

The corresponding CLs for each analysis were calculated with the proper confidence coefficient respectively. As in 2D gamma evaluations, institutional tolerance levels for IMRT and prostate plans were higher than those for VMAT and H&N plans, respectively, since the average gamma passing rate of IMRT and prostate plans were higher than those of VMAT and H&N plans.

**Correlation analysis**

Since no pairs of both groups followed normal distributions, only Spearman correlation coefficients ($r$) were calculated for correlation analysis between 2D and quasi-3D gamma passing rates.

![Figure 3: The film was placed between two pieces of a custom-made cylindrical phantom.](image)

The cylindrical phantom was made of acrylic. The lever was equipped to reduce air gaps between two pieces of the phantom.
The calculated correlation coefficients and the corresponding p values between 2D and quasi-3D gamma passing rates of IMRT and VMAT are shown in Table 2 with the average value of MU/cGy which represent the degree of modulation. However, the difference in MU/cGy between IMRT and VMAT didn’t show the difference in the modulation degree because the technique is different each other. Statistically significant correlation was observed between 2D vs. quasi-3D gamma passing rates with 3%/3 mm in the VMAT group ($r = 0.564$ with $p = 0.012$). The others showed no statistically significant correlations.

The correlation coefficients between 2D vs. quasi-3D gamma passing rates of prostate and H&N groups are shown in Table 2 with the average value of MU/cGy. The average value of MU/cGy of prostate plans was lower than that of H&N plans, which indicated higher modulation of H&N plans than prostate plans (3.48 MU/cGy vs. 5.43 MU/cGy with $p = 0.005$). No statistically significant correlations were observed (always with $p > 0.05$).

The $r$ values between 2D vs. quasi-3D gamma passing rates regardless of the delivery technique and treatment site with 2%/2 mm and 3%/3 mm were 0.239 (with $p = 0.143$) and 0.372 (with $p = 0.020$), respectively. Statistically significant correlation was observed between 2D vs. quasi-3D gamma passing rates with 3%/3 mm, however, the correlation was weak.

**DISCUSSION**

In this study, 2D and quasi-3D gamma passing rates of IMRT and VMAT for prostate and H&N cancers were grouped by delivery techniques and treatment sites. The differences in gamma passing rates according to the grouping were statistically analyzed and the CLs for each group were calculated. After that, the correlations between 2D and quasi-3D gamma passing rates were analyzed. Since this study was to investigate the characteristics of 2D and quasi-3D gamma passing rates under the assumption that there was no systematic errors in IMRT and VMAT planning and delivery, we verified delivery accuracy additionally using log files. As shown by the results, the deviations between mechanical parameters of the original plans and those of log files were minimal. In addition, the reconstructed dose distributions using the log files showed no considerable differences in the dose-volumetric parameters compared to those of the original treatment plans. Therefore, the delivery accuracy of both...
IMRT and VMAT seems acceptable for the treatment of patients [18, 19, 21].

Statistically significant difference was observed between prostate \(\text{vs.}\) H\&N plans with 2D gamma evaluation. Since H\&N plans were more highly-modulated than did the prostate plans (MU/cGy of prostate and H\&N plans = 3.48 vs. 5.43), this result was reasonable and similar to those of previous studies [15, 16]. For the quasi-3D gamma passing rates with 2%/2 mm between IMRT and VMAT, we observed statistically significant difference, which was a contradictory result of the previous studies [8, 34]. However, the magnitude of the difference was only 2%, which was minimal.

According to the American Association of Physicist in Medicine (AAPM) Task Group (TG) 119 report, the tolerance level can be acquired by calculating the values of CL [6]. Since the sample size was small and the data were acquired from a single institution, we didn’t calculate CLs to acquire tolerance levels for the verification of IMRT and VMAT. Instead, we calculated the CLs for each group to investigate the differences between groups. For 2D absolute gamma evaluations with EBT2 films by measuring an axial dose distribution, CLs with 2%/2 mm and 3%/3 mm were 68.0% and 81.9%, respectively. These values were lower than those recommended by AAPM TG-119 report [6]. Since we additionally verify plan delivery accuracy with log files which showed negligible deviations, we believe that these low gamma passing rates of EBT2 films were caused by uncertainties of film dosimetry not errors of the TPS or beam delivery system. A lot of studies have reported uncertainties of EBT2 film dosimetry due to scanning orientation, non-uniformity of the scanner, film development time, and film uniformity [35, 36]. Moreover, since we performed absolute gamma evaluations with the EBT2 film not the relative gamma evaluation, this might lower the values of gamma passing rates. For quasi-3D absolute gamma evaluations with the COMPASS \(\text{TM}\) system, much higher values of the CLs than those of 2D gamma evaluations were acquired with both 2%/2 mm and 3%/3 mm, which were 91.5% and 97.5%, respectively. Persoon et al. also noted the implementation of 3D gamma evaluations using the same acceptance criteria as those for 2D gamma evaluations would be expected to lead to a higher passing rate [37].

For correlation analysis, no statistically significant correlations were observed between 2D and quasi-3D gamma evaluations except VMAT. Although VMAT demonstrated weak correlations between 2D and quasi-3D gamma passing rates, it is hard to mention that 2D gamma passing rates could represent quasi-3D gamma passing rates. For more appropriate verifications of both IMRT and VMAT, the verification method based on quasi-3D or 3D information should be performed in the clinic.

MATERIALS AND METHODS

Treatment planning and delivery

Ten of each prostate and head and neck (H\&N) patients (a total of 20 patients) were retrospectively selected for both IMRT and VMAT planning. Thus, a total of 40 treatment plans were generated for this study. Each IMRT plan had eight coplanar non-opposing isocentric beams (gantry angles of 40°, 60°, 100°, 160°, 200°, 260°, 300° and 320°). Each VMAT plan was generated with two coplanar full arcs. Both IMRT and VMAT plans were generated using a 6 MV photon beam of Clinac iX \(\text{TM}\) with Millennium 120 \(\text{TM}\) MLC (Varian Medical Systems, Palo Alto, CA, USA). For prostate treatment with both IMRT and VMAT, a primary plan with a prescription dose of 44 Gy with a daily dose of 2 Gy to the primary target volume including both prostate and seminal vesicles was delivered to a patient. After that, a boost plan with a prescription dose of 36 Gy with a daily dose of 2 Gy to the boost target volume that included prostate only was delivered. In this study, only primary plans were analyzed. For H\&N treatment with both IMRT and VMAT, a simultaneous integrated boost (SIB) plan with a total of 3 target volumes was delivered to a patient, of which...
prescription doses were 67.5 Gy (daily dose of 2.25 Gy), 54 Gy (daily dose of 1.8 Gy) and 48 Gy (daily dose of 1.6 Gy). The optimization and dose calculation were done using the Eclipse™ system (version 8.9.17, Varian Medical Systems, Palo Alto, CA, USA). The progressive resolution optimizer (PRO) algorithm was used for the optimization of VMAT while the dose volume optimizer (DVO) algorithm was used for the optimization of IMRT (Varian Medical Systems, Palo Alto, CA, USA) [38, 39]. After optimization, doses for both techniques were calculated using the analytical anisotropic algorithm (AAA, Varian Medical Systems, Palo Alto, CA, USA) with a calculation grid of 2.5 mm [40].

Acquisition of log files

During beam delivery for the 2D and quasi-3D gamma evaluations for each plan, log files were acquired and analyzed. The actual positions of MLCs during delivery were acquired from the DynaLog files which contain information on the actual MLC positions recorded every 50 ms. In addition, we acquired linac log files which record the actual gantry angles and delivered monitor units (MUs) during VMAT delivery. We reconstructed volumetric dose distributions in patient CT images using the log files. The log files were formatted to correspond to the plan files in DICOM-RT format. Those DICOM-RT files were imported in the TPS and dose distributions were calculated. After that, radiation oncologists examined whether clinically significant deviations exist between the original and the reconstructed dose distributions.

2D gamma evaluation

The 2D planar dose measurements were performed with radiochromic films (EBT2 films, Ashland Advanced Materials, Covington, KY, USA) to measure dose distributions in an axial plane. The film was placed between two pieces of a custom-made cylindrical phantom, where the isocenter was located at the center of the phantom as shown in Figure 3. The custom-made phantom was designed to eliminate air gaps between the film and the phantom by pulling a lever. Film dosimetry carefully followed the process of self-development provided by manufacturer [41]. Since two batches of films were separately used for the measurements, in order to avoid the interbatch response variation of EBT2 films, which was known to be less than approximately 1%, the films from each batch-numbered packet were used for calibration [42]. The films were scanned 20 hours after irradiation using a flatbed scanner (Epson 10000XL™, Epson Canada Ltd., Toronto, Ontario, Canada) in 48 bit color mode with the practical spatial resolution of 75 dpi. The films were scanned in the landscape orientation for both calibration and measurement. When scanning, the films were located in the central region of the scanner to minimize the effect of non-uniformity of the scanner. To eliminate non-uniformity of the scanner, the background of the scanner was measured and subtracted from the measured dose distributions. The dual channel method of the red and blue correction was applied for calibration [43, 44]. The calculated and measured dose distributions were compared using Verisoft 3.1™ image software (PTW, Freiburg, Germany). The region of interest (ROI) of the film was defined as the size of a 12×10 cm² rectangle. The 2D gamma evaluation was performed with absolute dose values using the global gamma method. The gamma criteria used for gamma evaluation were 2%/2 mm and 3%/3 mm. The threshold dose which is a parameter to exclude dose points below a selected threshold for the gamma evaluation was set to be 10% of the maximum dose in this study.

Quasi-3D gamma evaluation

The COMPASS™ system which was configured with measured beam data was used for quasi-3D gamma evaluation. The ion chamber array (MatriXX™, IBA dosimetry, GmbH, Germany) with a build-up material (water-equivalent thickness of 2 cm) was attached to the gantry head orthogonal to the beam direction at the source to surface distance (SSD) of 100 cm. The accuracy of the detector setup was thoroughly evaluated with delivery of three different open fields, equipped with an angular position sensor. After verification of set-up accuracy, actually delivered fluences of IMRT and VMAT plans were measured with an ion chamber array. The sampling interval of the fluence measurements was 250 ms. The measured fluences were applied to the patient CT images, and then the 3D dose distribution at the patient CT images was reconstructed in the COMPASS™ system with the collapsed cone convolution (CCC) algorithm, i.e. 3D dose distribution at the patient CT images was calculated with the measured fluences using the the CCC algorithm. The reconstructed 3D dose data were compared to the planned 3D dose data calculated by treatment planning system (TPS) with gamma-index method (i.e. quasi-3D gamma evaluation). For the quasi-3D gamma evaluation, the global gamma evaluations with gamma criteria of 2%/2 mm and 3%/3 mm were performed for both IMRT and VMAT. The irradiated patient body was set as ROI of this evaluation. The threshold dose was set to be 10% of the maximum dose same as 2D gamma evaluation.

Data grouping and statistical analysis

The data was grouped by the delivery technique (IMRT vs. VMAT) and the treatment site (prostate vs. H&N) for statistical analysis. Thus, the grouping by the delivery technique was done regardless of the treatment
site. Similarly, the grouping by the treatment site was done regardless of the delivery technique. The Shapiro-Wilk (SW) test was performed to determine whether a data set of each group is well-modeled by the normal distribution, that is, with the $p$ value greater than 0.05 [45]. To assess statistical significance of the differences between two groups, a two sided Student’s t-test was used if both groups followed the normal distribution, otherwise, the Wilcoxon rank-sum test was used [46]. The $p$ value is equal to or less than 0.05 regarded as statistically significant in this study. For the calculation of CLs, the confidence coefficient of 1.96 was applied to normally distributed groups; otherwise, the confidence coefficient of 2.093 and 2.023 in the Student’s t-distribution table of two tails were applied to 20 and 40 samples, respectively, within a 95% confidence level [47]. For correlation analysis, if both groups followed the normal distribution, the Pearson correlation coefficient was calculated; otherwise the Spearman correlation coefficient was calculated to examine the correlations [48]. The correlation analyses were performed between 2D and quasi-3D gamma evaluations with both IMRT and VMAT, with only IMRT and with only VMAT. In addition, correlation analysis between 2D and quasi-3D gamma evaluations were performed with only prostate plans including both IMRT and VMAT (lowly-modulated plans) as well as only H&N plans including both IMRT and VMAT (highly-modulated plans). The schematic diagram of statistical analysis is shown in Figure 4.

ACKNOWLEDGMENTS

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0059).

CONFLICTS OF INTEREST

The authors indicated no conflicts of interest.

REFERENCES

1. Sung W, Park JM, Choi CH, Ha SW and Ye SJ. The effect of photon energy on intensity-modulated radiation therapy (IMRT) plans for prostate cancer. Radiat Oncol J. 2012; 30(1):27-35.
2. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008; 35(1):310-317.
3. Park JM, Wu HG, Kim JH, Carlson JN and Kim K. The effect of MLC speed and acceleration on the plan delivery accuracy of VMAT. Br J Radiol. 2015; 20140698.
4. Park SY, Park JM, Kim JI, Kim H, Kim IH and Ye SJ. Textural feature calculated from segmental fluences as a modulation index for VMAT. Phys Med. 2015; 31(8):981-990.
5. Park JM, Park SY and Kim H. Modulation index for VMAT considering both mechanical and dose calculation uncertainties. Phys Med Biol. 2015; 60(18):7101-7125.
6. Ezzell GA, Burmeister JW, Dogan N, LoSasso TJ, Mechelakos JG, Mihailidis D, Molineu A, Palta JR, Ramsey CR, Salter BJ, Shi J, Xia P, Yue NJ and Xiao Y. IMRT commissioning: multiple institution planning and dosimetry comparisons, a report from AAPM Task Group 119. Med Phys. 2009; 36(11):5359-5373.
7. Jin H, B F, Jesseph and Ahmad S. A Comparison Study of Volumetric Modulated Arc Therapy Quality Assurances Using Portal Dosimetry and MapCHECK 2. Prog Med Phys. 2014; 25(2):7.
8. Mancuso GM, Fontenot JD, Gibbons JP and Parker BC. Comparison of action levels for patient-specific quality assurance of intensity modulated radiation therapy and volumetric modulated arc therapy treatments. Med Phys. 2012; 39(7):4378-4385.
9. Paik EK, Kim MS, Choi CW, Jang WI, Lee SH, Choi SH, Kim KB and Lee DH. Dosimetric comparison of volumetric modulated arc therapy with robotic stereotactic radiation therapy in hepatocellular carcinoma. Radiat Oncol J. 2015; 33(3):233-241.
10. Shandiz MH, Layen GS, Anvari K and Khalilzadeh M. New methods for optical distance indicator and gantry angle quality control tests in medical linear accelerators: image processing by using a 3D phantom. Radiat Oncol J. 2015; 33(1):42-49.
11. Low DA, Harms WB, Mutic S and Purdy JA. A technique for the quantitative evaluation of dose distributions. Med Phys. 1998; 25(5):656-661.
12. Nelms BE, Zhen H and Tome WA. Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors. Med Phys. 2011; 38(2):1037-1044.
13. Stasi M, Bresciani S, Miranti A, Maggio A, Sapino V and Gabriele P. Pretreatment patient-specific IMRT quality assurance: a correlation study between gamma index and patient clinical dose volume histogram. Med Phys. 2012; 39(12):7626-7634.
14. Betzel GT, Yi BY, Niu Y and Yu CX. Is RapidArc more susceptible to delivery uncertainties than dynamic IMRT? Med Phys. 2012; 39(10):5882-5890.
15. Fredh A, Scherman JB, Fog LS and Munck af Rosenschold P. Patient QA systems for rotational radiation therapy: a comparative experimental study with intentional errors. Med Phys. 2013; 40(3):031716.
16. Heilemann G, Poppe B and Laub W. On the sensitivity of common gamma-index evaluation methods to MLC misalignments in Rapidarc quality assurance. Med Phys. 2013; 40(3):031702.
17. Kim JI, Park SY, Kim HJ, Kim JH, Ye SJ and Park JM. The sensitivity of gamma-index method to the positioning errors of high-definition MLC in patient-specific VMAT QA for SBRT. Radiat Oncol. 2014; 9:167.
18. Peng J, Zhang Z, Zhou L, Zhao J, Wang J, Kong L and Hu W. A study on investigating the delivery parameter error effect on the variation of patient quality assurance during RapidArc treatment. Med Phys. 2013; 40(3):031703.
19. Teke T, Bergman AM, Kwa W, Gill B, Duzenli C and Popescu IA. Monte Carlo based, patient-specific RapidArc QA using Linac log files. Med Phys. 2010; 37(1):116-123.
20. Du W, Cho SH, Zhang X, Hoffman KE and Kudchadker RJ. Quantification of beam complexity in intensity-modulated radiation therapy treatment plans. Med Phys. 2014; 41(2):021716.
21. Park JM, Park SY, Kim H, Kim JH, Carlson J and Ye SJ. Modulation indices for volumetric modulated arc therapy. Phys Med Biol. 2014; 59(23):7315-7340.
22. Park SY, Kim IH, Ye SJ, Carlson J and Park JM. Texture analysis on the fluence map to evaluate the degree of modulation for volumetric modulated arc therapy. Med Phys. 2014; 41(11):111718.
23. Park SY, Park JM, Sung W, Kim IH and Ye SJ. Texture analysis on the edge-enhanced fluence of VMAT. Radiat Oncol. 2015; 10(1):74.
24. Webb S. Use of a quantitative index of beam modulation to characterize dose conformity: illustration by a comparison of full beamlet IMRT, few-segment IMRT (fsIMRT) and conformal unmodulated radiotherapy. Phys Med Biol. 2003; 48(14):2051-2062.
25. Watanabe Y and Nakaguchi Y. 3D evaluation of 3DVH program using BANG3 polymer gel dosimeter. Med Phys. 2013; 40(8):082101.
26. Furuta T, Maeyama T, Ishikawa KL, Fukunishi N, Fukasaku K, Takagi S, Noda S, Himeno R and Hayashi S. Comparison between Monte Carlo simulation and measurement with a 3D polymer gel dosimeter for dose distributions in biological samples. Phys Med Biol. 2015; 60(16):6531-6546.
27. Sdrolia A, Brownsworth KM, Marsden JE, Alty KT, Moore CS and Beavis AW. Retrospective review of locally set tolerances for VMAT prostate patient specific QA using the COMPASS(R) system. Phys Med. 2015; 31(7):792-797.
28. Gueorguiev G, Cotter C, Turcotte JC, Crawford B, Sharp G and Mah DM. Clinical implementation and error sensitivity of a 3D quality assurance protocol for prostate and thoracic IMRT. J App Clin Med Phys. 2015; 16(5):5392.
29. Neilson C, Klein M, Barnett R and Yartsev S. Delivery quality assurance with ArcCHECK. Med Dosim. 2013; 38(1):77-80.
30. Fakir H, Gaede S, Mulligan M and Chen JZ. Development of a novel ArcCHECK® insert for routine quality assurance of VMAT delivery including dose calculation with inhomogeneities. Med Phys. 2012; 39(7):4203-4208.
31. Sadagopan R, Bencomo JA, Martin RL, Nilsson G, Matzen T and Balter PA. Characterization and clinical evaluation of a novel IMRT quality assurance system. J App Clin Med Phys. 2009; 10(2):2928.
32. Rajasekaran D, Jeevanandam P, Sukumar P, Ranganathan A, Johnjothi S and Nagarajan V. A study on correlation between 2D and 3D gamma evaluation metrics in patient-specific quality assurance for VMAT. Med Dosim. 2014; 39(4):300-308.
33. Jin X, Yan H, Han C, Zhou Y, Yi J and Xie C. Correlation between gamma index passing rate and clinical dosimetric difference for pre-treatment 2D and 3D volumetric modulated arc therapy dosimetric verification. Br J Radiol. 2015; 88(1047):20140577.
34. Betzel GT, Yi BY, Niu Y and Yu CX. Is RapidArc more susceptible to delivery uncertainties than dynamic IMRT? Med Phys. 2012; 39(10):5882-5890.
35. Richley L, John AC, Coomber H and Fletcher S. Evaluation and optimization of the new EBT2 radiochromic film dosimetry system for patient dose verification in radiotherapy. Phys Med Biol. 2010; 55(9):2601-2617.
36. Aland T, Kairn T and Kenny J. Evaluation of a Gafchromic EBT2 film dosimetry system for radiotherapy quality assurance. Australas Phys Eng Sci Med. 2011; 34(2):251-260.
37. Persoon LCGG, Podesta M, van Elmpt WJC, Nijsten SMJG and Verhaegen F. A fast three-dimensional gamma evaluation using a GPU utilizing texture memory for on-the-fly interpolations. Med Phys. 2011; 38(7):4032-4035.
38. Vanetti E, Nicolini G, Nord J, Peltola J, Clivio A, Fogliata A and Cozzi L. On the role of the optimization algorithm of RapidArc((R)) volumetric modulated arc therapy on plan quality and efficiency. Med Phys. 2011; 38(11):5844-5856.
39. Jeraj R, Wu C and Mackie TR. Optimizer convergence and local minima errors and their clinical importance. Phys Med Biol. 2003; 48(17):2809-2827.
40. Fogliata A, Nicolini G, Vanetti E, Clivio A and Cozzi L. Dosimetric validation of the anisotropic analytical algorithm for photon dose calculation: fundamental characterization in water. Phys Med Biol. 2006; 51(6):1421-1438.
41. ISP Corp 2009 GafChromic EBT2, Self developing film for radiotherapy dosimetry ISP White Paper (Wayne, NJ: ISP Corporation)
42. van Battum LJ, Hoffmans D, Piersma H and Heuvelom S. Accurate dosimetry with GafChromic EBT film of a 6 MV photon beam in water: what level is achievable? Med Phys. 2008; 35(2):704-716.
43. Mayer RR, Ma F, Chen Y, Miller RI, Belard A, McDonough J and O’Connell JJ. Enhanced dosimetry procedures and assessment for EBT2 radiochromic film. Med Phys. 2012; 39(4):2147-2155.
44. Micke A, Lewis DF and Yu X. Multichannel film dosimetry with nonuniformity correction. Med Phys. 2011; 38(5):2523-2534.
45. Shapiro SS and Wilk MB. An Analysis of Variance Test for Normality (Complete Samples). Biometrika. 1965; 52:591-.

46. Bridge PD and Sawilowsky SS. Increasing physicians’ awareness of the impact of statistics on research outcomes: comparative power of the t-test and and Wilcoxon Rank-Sum test in small samples applied research. J Clin Epidemiol. 1999; 52(3):229-235.

47. Dunnett CW and Sobel M. A bivariate generalization of Student’s t-distribution, with tables for certain special cases. Biometrika. 1954; 41(1-2):153-169.

48. Spearman C. The proof and measurement of association between two things. Int J Epidemiol. 2010; 39(5):1137-1150.